COMPASS Pathways Plc - American Depository Shares (CMPS)
3.9300
+0.0100 (0.26%)
COMPASS Pathways is a biotechnology company dedicated to advancing mental health treatment through innovative therapies
It focuses on developing psilocybin therapy, a novel approach to addressing conditions such as treatment-resistant depression. By conducting clinical trials and research, the company seeks to create evidence-based solutions that harness the potential of psychedelic substances in a controlled and therapeutic context. COMPASS Pathways aims to improve patient outcomes and transform mental health care through its pioneering work in the field of psychedelics and mental health.
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca.
